Inventor · disambiguated record
Chien-Tsun Kuan
Also filed as: KUAN CHIEN-TSUN
20 granted patents·15 pending applications·201 citations·filing 1996–2025
94Inventor score
Top patents by PatentIndex Score
35 records- 0196US10704108B2Genetic alterations in isocitrate dehydrogenase and other genes in malignant gliomaUNIV JOHNS HOPKINS·Filed 2018·Granted Jul 7, 2020·22 cites·16 claims
- 0294US10837064B2Genetic alterations in isocitrate dehydrogenase and other genes in malignant gliomaUNIV JOHNS HOPKINS·Filed 2018·Granted Nov 17, 2020·9 cites·14 claims
- 0393US8685660B2Genetic alterations in isocitrate dehydrogenase and other genes in malignant gliomaVOGELSTEIN BERT·Filed 2009·Granted Apr 1, 2014·21 cites·14 claims
- 0491US10894987B2Genetic alterations in isocitrate dehydrogenase and other genes in malignant gliomaUNIV JOHNS HOPKINS·Filed 2016·Granted Jan 19, 2021·5 cites·8 claims
- 0591US9353418B2Genetic alterations in isocitrate dehydrogenase and other genes in malignant gliomaUNIV JOHNS HOPKINS·Filed 2013·Granted May 31, 2016·13 cites·24 claims
- 0690US2024392381A1Genetic alterations in isocitrate dehydrogenase and other genes in malignant gliomaUNIV JOHNS HOPKINS·Filed 2024·Application pending·0 cites
- 0788US8039593B2Antibodies and immunotoxins that target human glycoprotein NMBUNIV DUKE·Filed 2006·Granted Oct 18, 2011·10 cites·32 claims
- 0886US6074644ANucleic acids encoding immunotoxins containing a disulfide-stabilized antibody fragment replacing half or more of domain IB of pseudomonas exotoxin, and methods of use of the encoded immunotoxinsUS HEALTH·Filed 1999·Granted Jun 13, 2000·59 cites·25 claims
- 0985US5980895AImmunotoxin containing a disulfide-stabilized antibody fragment joined to a Pseudomonas exotoxin that does not require proteolytic activationUS HEALTH·Filed 1996·Granted Nov 9, 1999·45 cites·30 claims
- 1084US9249217B2Bispecific EGFRvIII x CD3 antibody engaging moleculesBIGNER DARELL D·Filed 2011·Granted Feb 2, 2016·10 cites·6 claims
- 1183US10072084B2Dual specific immunotoxin for brain tumor therapyUNIV DUKE·Filed 2016·Granted Sep 11, 2018·2 cites·13 claims
- 1278US9492564B2Dual specific immunotoxin for brain tumor therapyUNIV DUKE·Filed 2014·Granted Nov 15, 2016·2 cites·17 claims
- 1376US10053514B2Human bispecific EGFRvIII and CD3 antibody engaging moleculesUNIV DUKE·Filed 2014·Granted Aug 21, 2018·3 cites·8 claims
- 1475US2021317532A1Genetic alterations in isocitrate dehydrogenase and other genes in malignant gliomaUNIV JOHNS HOPKINS·Filed 2020·Application pending·0 cites
- 1566US2009269343A1Dual Specific Immunotoxin for Brain Tumor TherapyUNIV DUKE·Filed 2009·Application pending·0 cites
- 1663US2024398863A1Chimeric antigen receptor and cell including chimeric antigen receptorARCE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1761US2013022598A1Dual Specific Immunotoxin for Brain Tumor TherapyUS SECRETARY DEPT OF HEALTH AND HUMAN SERVICE·Filed 2012·Application pending·0 cites
- 1859US9115196B2Antibodies and immunotoxins that target human glycoprotein NMBUS HEALTH·Filed 2013·Granted Aug 25, 2015·0 cites·9 claims
- 1959US2012202207A1Genetic alterations in isocitrate dehydrogenase and other genes in malignant gliomaVOGELSTEIN BERT·Filed 2012·Application pending·0 cites
- 2054US10752688B2Anti-human TIM-3 antibodies and methods of use thereofDEV CT BIOTECHNOLOGY·Filed 2017·Granted Aug 25, 2020·0 cites·8 claims
- 2153US2010047164A1Anti-Tumor AntibodiesUNIV DUKE·Filed 2009·Application pending·0 cites
- 2253US2008145875A1Anti-tenascin monoclonal antibody immunoassays and diagnostic kitsUNIV DUKE·Filed 2008·Application pending·0 cites
- 2352US9441048B2Antibody for 3′-isoLM1 and 3′,6′-iso-LD1 gangliosidesBIGNER DARELL·Filed 2011·Granted Sep 13, 2016·0 cites·5 claims
- 2451US8445216B2Antibodies and immunotoxins that target human glycoprotein NMBKUAN CHIEN-TSUN·Filed 2011·Granted May 21, 2013·0 cites·6 claims
- 2549US2015368353A1Anti-Podoplanin Antibodies and Methods of UseUNIV DUKE·Filed 2015·Application pending·0 cites
- 2648US10052382B2Methods for using antibodies for 3′ iso-LM1 and 3′, 6′-iso-LD1tumor gangliosidesUNIV DUKE·Filed 2016·Granted Aug 21, 2018·0 cites·7 claims
- 2748US9676858B2Human bispecific EGFRvIII antibody and CD3 engaging moleculesUNIV DUKE·Filed 2013·Granted Jun 13, 2017·0 cites·7 claims
- 2848US2006115862A1Anti-tenascin monoclonal antibody immunoassays and diagnostic kitsUNIV DUKE·Filed 2005·Application pending·0 cites
- 2946US8835608B2Anti-MRP3 antibodies and methods of useKUAN CHIEN-TSUN·Filed 2007·Granted Sep 16, 2014·0 cites·14 claims
- 3046US2018362659A1Certain Improved Human Bispecific EGFRvIII Antibody Engaging MoleculesTHE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES·Filed 2018·Application pending·0 cites
- 3144US10138300B2Anti-VEGFR antibody and uses thereofDEV CT BIOTECHNOLOGY·Filed 2017·Granted Nov 27, 2018·0 cites·10 claims
- 3242US2025288612A1Chimeric antigen receptor against programmed death ligand 1 (pd-l1) and application thereofTOPMUNNITY THERAPEUTICS TAIWAN LTD·Filed 2025·Application pending·0 cites
- 3342US2014017266A1Anti-podoplanin antibodies and methods of useBIGNER DARELL·Filed 2011·Application pending·0 cites
- 3439US2017233480A1Anti-vegfr antibody and uses thereofDEV CT BIOTECHNOLOGY·Filed 2016·Application pending·0 cites
- 3536US2019309092A1Modified antigen-binding fab fragments and antigen-binding molecules comprising the sameDCB USA LLC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Chien-Tsun Kuan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →